Claude Bertrand

Executive Vice President Research & Development, Chief Scientific Officer since November 2009.

Claude Bertrand started his career at Novartis (previously Ciba-Geigy) in Basel, Switzerland. Then, he moved to the Inflammatory Disease Unit at Roche (Palo Alto, California, USA). In 1999, he was recruited as Senior Director of Biology R&D of Pfizer in France and was a member of the management team of Pfizer Global R&D. From 2004 to 2009, Claude Bertrand was R&D Vice-President, then R&D Senior Vice-President of AstraZeneca, where he was responsible for the Respiratory and Inflammatory Therapeutic Area.

Claude Bertrand is Chairman of ARIIS (Alliance pour la Recherche et l’Innovation des Industries de Santé) and he is Director of INSERM.

Claude Bertrand has a PhD in pharmacy, a Master Pharmacology, a PhD from the Louis Pasteur University of Strasbourg, France. Then, Claude Bertrand obtained a post doc from the University of California, San Francisco, USA, under the supervision of Professor Jay A. Nadel.

Updated on 29 March 2013